ME02488B - Antikancerski steroidni laktoni nezasićeni na poziciji 7(8) - Google Patents
Antikancerski steroidni laktoni nezasićeni na poziciji 7(8)Info
- Publication number
- ME02488B ME02488B MEP-2016-88A MEP8816A ME02488B ME 02488 B ME02488 B ME 02488B ME P8816 A MEP8816 A ME P8816A ME 02488 B ME02488 B ME 02488B
- Authority
- ME
- Montenegro
- Prior art keywords
- unsaturated
- saturated
- hydrogen
- alkyl
- compound according
- Prior art date
Links
- -1 LACTONES STEROID Chemical class 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 239000001257 hydrogen Substances 0.000 claims 29
- 229920006395 saturated elastomer Polymers 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 229910052736 halogen Chemical group 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002016 disaccharides Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000004043 trisaccharides Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (17)
1. Jedinjenje opšte formule I pri čemuR1 je izabran između vodonika i halogena;R2 je halogen;svaki R3, R15, i R16 je nezavisno izabran između vodonika, ORa, OCORa, OCOORa, i =O, uz uslov da kada postoji =O grupa, onda vodonik C atoma za koji je vezan =O nije prisutan;svaki R4, R5, R6, R7, R11, R12, i R14 je nezavisno izabran između vodonika, ORa, OCORa, i OCOORa;svaki R8, R9, i R17 je nezavisno izabran između vodonika, ORa, OCORa, OCOORa, zasićenog ili nezasićenog C1-C12 alkila, zasićenog ili nezasićenog C2-C12 alkenila, i zasićenog ili nezasićenog C2-C12 alkinila;R10 je izabran između vodonika, ORb, OCORa, OCOORa, i =O, uz uslov da kada postoji =O grupa, onda vodonik C atoma za koji je vezan =O nije prisutan;R13 je izabran između vodonika, CORa, zasićenog ili nezasićenog C1-C12 alkila, zasićenog ili nezasićenog C2-C12 alkenila, i zasićenog ili nezasićenog C2-C12 alkinila;svaki Ra je nezavisno izabran između vodonika, zasićenog ili nezasićenog C1-C12 alkila, zasićenog ili nezasićenog C2-C12 alkenila, zasićenog ili nezasićenog C2-C12 alkinila, zasićenog ili nezasićenog arila, i zasićene ili nezasićene heterociklične grupe;svaki Rb je nezavisno izabran između vodonika, zasićenog ili nezasićenog C1-C12 alkila, zasićenog ili nezasićenog C2-C12 alkenila, zasićenog ili nezasićenog C2-C12 alkinila, zasićenog ili nezasićenog arila, zasićene ili nezasićene heterociklične grupe, i zasićenog ili nezasićenog šećera; i------- linija predstavlja dodatnu vezu, epoksi grupu, ili nije prisutna;ili njegova farmaceutski prihvatljiva so ili stereoizomer.
2. Jedinjenje prema zahtjevu 1, pri čemu je svaki R3, R5, R6, R14, i R15 nezavisno izabran između vodonika, ORa, i OCORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
3. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R17 zasićeni ili nezasićeni C1-C6 alkil.
4. Jedinjenje prema zahtjevu 1, koje ima sledeću formulu II pri čemu su R1, R2, R4, R7, R8-R13, R16, i ------- linija definisani kao u zahtevu 1, ili njegova farmaceutski prihvatljiva so ili stereoizomer.
5. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R1 izabran između vodonika i Cl; i pri čemu R2 je Cl.
6. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R4 izabran između vodonika i ORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
7. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R7 izabran između vodonika, ORa, i OCORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
8. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je svaki R8 i R9 nezavisno izabran između vodonika, zasićenog ili nezasićenog C1-C12 alkila, ORa, i OCORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
9. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R10 izabran između ORb, OCORa, i =O, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila i Rb je izabran između vodonika, zasićenog ili nezasićenog C1-C6 alkila, monosaharida, disaharida, i trisaharida, uz uslov da kada R10 je =O, onda vodonik C atoma za koji je vezan R10 nije prisutan.
10. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R13 izabran između vodonika, zasićenog ili nezasićenog C1-C12 alkila, i CORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
11. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu je R16 izabran između vodonika, ORa, i OCORa, i pri čemu je Ra izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
12. Jedinjenje prema bilo kom od prethodnih zahtjeva, pri čemu ------- linija nije prisutna, svaki R11 i R12 je nezavisno izabran između vodonika, ORa, i OCORa, i Ra je izabran između vodonika i zasićenog ili nezasićenog C1-C6 alkila.
13. Jedinjenje prema bilo kom od zahtjeva 1 do 11, pri čemu ------- linija predstavlja dodatnu vezu ili epoksi grupu, i R11 i R12 su vodonik.
14. Jedinjenje prema zahtjevu 1, koje ima sljedeću strukturu: ili njegova farmaceutski prihvatljiva so.
15. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od prethodnih zahtjeva, ili njegovu farmaceutski prihvatljivu so ili stereoizomer, i farmaceutski prihvatljivi nosač ili razređivač.
16. Jedinjenje prema bilo kom od zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva so ili stereoizomer, za primenu kao lijek.
17. Jedinjenje prema zahtjevu 16 za primjenu u liječenju kancera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382095 | 2010-04-27 | ||
| PCT/EP2011/056566 WO2011134954A1 (en) | 2010-04-27 | 2011-04-26 | Anticancer steroidal lactones unsaturated in position 7 (8) |
| EP11716407.9A EP2563803B1 (en) | 2010-04-27 | 2011-04-26 | Anticancer steroidal lactones unsaturated in position 7(8) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02488B true ME02488B (me) | 2017-02-20 |
Family
ID=44544049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-88A ME02488B (me) | 2010-04-27 | 2011-04-26 | Antikancerski steroidni laktoni nezasićeni na poziciji 7(8) |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8962602B2 (me) |
| EP (1) | EP2563803B1 (me) |
| JP (1) | JP5815675B2 (me) |
| KR (1) | KR101855453B1 (me) |
| CN (1) | CN102947322B (me) |
| AU (1) | AU2011247634B2 (me) |
| BR (1) | BR112012027393B1 (me) |
| CA (1) | CA2797468C (me) |
| CL (1) | CL2012003006A1 (me) |
| CY (1) | CY1117541T1 (me) |
| DK (1) | DK2563803T3 (me) |
| ES (1) | ES2574205T3 (me) |
| HR (1) | HRP20160523T1 (me) |
| HU (1) | HUE028751T2 (me) |
| IL (1) | IL222707B (me) |
| ME (1) | ME02488B (me) |
| MX (1) | MX2012012523A (me) |
| MY (1) | MY162934A (me) |
| NZ (1) | NZ603261A (me) |
| PL (1) | PL2563803T3 (me) |
| RS (1) | RS54780B1 (me) |
| RU (1) | RU2572595C2 (me) |
| SG (2) | SG185032A1 (me) |
| SI (1) | SI2563803T1 (me) |
| SM (1) | SMT201600139B (me) |
| UA (1) | UA112746C2 (me) |
| WO (1) | WO2011134954A1 (me) |
| ZA (1) | ZA201208092B (me) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN105017368B (zh) * | 2015-06-26 | 2016-09-28 | 南通大学 | 人参二醇衍生物及其制备方法与应用 |
| US20190076376A1 (en) | 2015-07-10 | 2019-03-14 | University Of Miami | Methods for treating mucopolysaccharidosis |
| CN105968167B (zh) * | 2016-05-05 | 2017-10-17 | 江苏省中医药研究院 | 环氧蟾毒烯酮的制备方法及其作为抗肿瘤药物的用途 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| EP4104892A1 (en) | 2020-12-17 | 2022-12-21 | Aseptic Connectors Limited | A connector |
| WO2022169705A1 (en) * | 2021-02-02 | 2022-08-11 | Neupharma, Inc | Certain chemical entities, compositions, and methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1577633A (en) * | 1976-12-17 | 1980-10-29 | Degussa | Acyl derivatives of hellebrigenin |
| JPH04290899A (ja) * | 1991-03-18 | 1992-10-15 | Sankyo Co Ltd | カルデノライド化合物 |
| JPH05112596A (ja) * | 1991-10-20 | 1993-05-07 | Reisa Cho | ブフアリンおよびブフアジエノリドを有効成分とす医薬 |
| AU2879300A (en) * | 1999-02-12 | 2000-08-29 | Cellpath, Inc. | Methods for anti-tumor therapy |
| IL135707A0 (en) | 2000-04-17 | 2001-05-20 | Yissum Res Dev Co | 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them |
| WO2002014343A1 (en) * | 2000-08-17 | 2002-02-21 | Terness, Peter | Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents |
| CA2418458A1 (fr) | 2003-02-06 | 2004-08-06 | Neokimia Inc. | Synthese totale de 14 beta-fluorosteroides via la reaction de diels-alder transannulaire |
| GB0509829D0 (en) | 2005-05-13 | 2005-06-22 | Guys And St Thomas Nhs Foundat | Compound |
| CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
| US20090018088A1 (en) * | 2006-10-27 | 2009-01-15 | University Of Louisville Research Foundation | Treating cancer with cardiac glycosides |
| EP2032143A1 (en) * | 2006-05-09 | 2009-03-11 | University Of Louisville Research Foundation, Inc. | Treating cancer with cardiac glycosides |
-
2011
- 2011-04-26 MX MX2012012523A patent/MX2012012523A/es active IP Right Grant
- 2011-04-26 SI SI201130811A patent/SI2563803T1/sl unknown
- 2011-04-26 HU HUE11716407A patent/HUE028751T2/en unknown
- 2011-04-26 HR HRP20160523TT patent/HRP20160523T1/hr unknown
- 2011-04-26 SG SG2012079083A patent/SG185032A1/en unknown
- 2011-04-26 ES ES11716407.9T patent/ES2574205T3/es active Active
- 2011-04-26 AU AU2011247634A patent/AU2011247634B2/en not_active Ceased
- 2011-04-26 NZ NZ603261A patent/NZ603261A/en not_active IP Right Cessation
- 2011-04-26 WO PCT/EP2011/056566 patent/WO2011134954A1/en not_active Ceased
- 2011-04-26 ME MEP-2016-88A patent/ME02488B/me unknown
- 2011-04-26 UA UAA201213556A patent/UA112746C2/uk unknown
- 2011-04-26 EP EP11716407.9A patent/EP2563803B1/en active Active
- 2011-04-26 RU RU2012150501/04A patent/RU2572595C2/ru active
- 2011-04-26 US US13/642,910 patent/US8962602B2/en active Active
- 2011-04-26 CN CN201180031259.7A patent/CN102947322B/zh not_active Expired - Fee Related
- 2011-04-26 MY MYPI2012004732A patent/MY162934A/en unknown
- 2011-04-26 CA CA2797468A patent/CA2797468C/en active Active
- 2011-04-26 SG SG10201503290TA patent/SG10201503290TA/en unknown
- 2011-04-26 JP JP2013506629A patent/JP5815675B2/ja not_active Expired - Fee Related
- 2011-04-26 DK DK11716407.9T patent/DK2563803T3/en active
- 2011-04-26 PL PL11716407T patent/PL2563803T3/pl unknown
- 2011-04-26 RS RS20160305A patent/RS54780B1/sr unknown
- 2011-04-26 BR BR112012027393-0A patent/BR112012027393B1/pt not_active IP Right Cessation
- 2011-04-26 KR KR1020127031051A patent/KR101855453B1/ko not_active Expired - Fee Related
-
2012
- 2012-10-25 IL IL222707A patent/IL222707B/en active IP Right Grant
- 2012-10-26 ZA ZA2012/08092A patent/ZA201208092B/en unknown
- 2012-10-26 CL CL2012003006A patent/CL2012003006A1/es unknown
-
2016
- 2016-05-17 SM SM201600139T patent/SMT201600139B/it unknown
- 2016-05-24 CY CY20161100445T patent/CY1117541T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02488B (me) | Antikancerski steroidni laktoni nezasićeni na poziciji 7(8) | |
| HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20241197T1 (hr) | Makrociklični spojevi i primjene istih | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| JP2013507423A5 (me) | ||
| ME02800B (me) | Nova triciklična jedinjenja | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
| JP2016530314A5 (me) | ||
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20110845T1 (hr) | Antitumorski dihidropiran-2-onski spojevi | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| ME02321B (me) | Antivirusna jedinjenja | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| BR112015026410A2 (pt) | derivados de dolastatina 10 e auristatinas | |
| HRP20140466T1 (hr) | Antimikrobni spojevi | |
| JP2015516427A5 (me) | ||
| HRP20201165T1 (hr) | Uporaba inhibitora ccr3 | |
| JP2016513108A5 (ja) | 治療用化合物 | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |